| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
165,908,000 |
| Market
Cap: |
197.43(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.68 - $1.71 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
397,964 |
| Total Buy Value |
$0 |
$0 |
$0 |
$668,580 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
15,779 |
39,282 |
39,282 |
406,183 |
| Total Sell Value |
$16,832 |
$41,801 |
$41,801 |
$678,119 |
| Total People Sold |
2 |
2 |
2 |
6 |
| Total Sell Transactions |
2 |
4 |
4 |
11 |
| End Date |
2025-10-19 |
2025-07-18 |
2025-01-17 |
2024-01-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tahl Cindy |
See Remarks |
• – – |
2026-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
487,081 |
|
- |
|
| Adawi Kamal |
Chief Financial Officer |
• – – |
2026-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
100,000 |
|
- |
|
| Valamehr Bahram |
President and CEO |
• • – |
2026-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
335,000 |
664,708 |
|
- |
|
| Tahl Cindy |
See Remarks |
• – – |
2026-01-09 |
4 |
S |
$1.06 |
$11,275 |
D/D |
(10,589) |
387,081 |
|
- |
|
| Valamehr Bahram |
President and CEO |
• • – |
2026-01-09 |
4 |
S |
$1.07 |
$5,557 |
D/D |
(5,190) |
329,708 |
|
- |
|
| Adawi Kamal |
Chief Financial Officer |
• – – |
2025-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
|
- |
|
| Tahl Cindy |
See Remarks |
• – – |
2025-08-04 |
4 |
S |
$1.06 |
$9,573 |
D/D |
(9,037) |
397,670 |
|
-3% |
|
| Valamehr Bahram |
President and CEO |
• • – |
2025-08-04 |
4 |
S |
$1.06 |
$15,396 |
D/D |
(14,466) |
334,898 |
|
-3% |
|
| Redco Ii Master Fund, L.p. |
Director |
– • • |
2025-07-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,977,624 |
|
-4% |
|
| Bressi Jerome Charles |
See Remarks |
• – – |
2025-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
335,203 |
|
- |
|
| Tahl Cindy |
See Remarks |
• – – |
2025-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
406,707 |
|
- |
|
| Bressi Jerome Charles |
See Remarks |
• – – |
2025-01-10 |
4 |
S |
$1.55 |
$9,269 |
D/D |
(5,980) |
270,203 |
|
20% |
|
| Valamehr Bahram |
President and CEO |
• • – |
2025-01-10 |
4 |
S |
$1.54 |
$13,406 |
D/D |
(8,705) |
349,364 |
|
20% |
|
| Tahl Cindy |
See Remarks |
• – – |
2025-01-10 |
4 |
S |
$1.55 |
$8,764 |
D/D |
(5,654) |
336,707 |
|
20% |
|
| Green Jeremy |
Director |
– • • |
2024-12-20 |
4 |
B |
$1.68 |
$668,580 |
I/I |
397,964 |
12,884,277 |
2.25 |
-30% |
|
| Green Jeremy |
Director |
– • • |
2024-12-20 |
4 |
S |
$1.68 |
$573,943 |
I/I |
(341,633) |
12,486,313 |
|
30% |
|
| Green Jeremy |
Director |
– • • |
2024-12-20 |
4 |
A |
$1.68 |
$1,822,692 |
I/I |
1,084,936 |
12,827,946 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2024-12-20 |
4 |
D |
$1.68 |
$1,822,692 |
I/I |
(1,084,936) |
11,743,010 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2024-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
30,110 |
12,827,946 |
|
- |
|
| Bressi Jerome Charles |
See Remarks |
• – – |
2024-08-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
276,183 |
|
-49% |
|
| Xu Yuan |
|
– • – |
2024-08-06 |
4 |
AS |
$4.23 |
$2,678 |
D/D |
(633) |
8,669 |
|
-57% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2024-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
342,361 |
|
- |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2024-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
358,069 |
|
- |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2024-03-04 |
4 |
AS |
$7.77 |
$19,013 |
D/D |
(2,447) |
101,479 |
|
-45% |
|
| Dulac Edward J Iii |
Chief Financial Officer |
• – – |
2024-01-29 |
4 |
AS |
$5.00 |
$9,245 |
D/D |
(1,849) |
103,926 |
|
-36% |
|
291 Records found
|
|
Page 1 of 12 |
|
|
0.14 (13.33%) 
